Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Options for Affected Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Concerns

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge. This legacy of accessible health information has empowered individuals to make informed decisions about their well-being, from preventive care to understanding complex medical conditions. Within this tradition, the focus has gradually expanded to include specific therapeutic interventions and their associated risks, particularly as treatments become more specialized. One such area of heightened awareness involves the use of disease-modifying therapies for chronic conditions. Among these, Tysabri has been recognized for its efficacy in managing certain autoimmune disorders. However, alongside its benefits, clinical experience has identified a rare but serious risk: Progressive Multifocal Leukoencephalopathy (PML). This condition, linked to the reactivation of the JC virus, has prompted careful monitoring and, in some cases, legal scrutiny. The transition from general health education to occupational exposure concern arises when individuals who have received Tysabri develop PML and seek accountability. This pivot is not about mechanistic details but about the practical implications of risk disclosure and patient safety. As such, the conversation naturally moves from broad health literacy to the specific legal and medical questions surrounding Tysabri exposure and PML risk, particularly for those evaluating their eligibility for a lawsuit. This shift reflects a growing need to bridge general knowledge with targeted, actionable concerns.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's strongest safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and there is no specific treatment for the infection once it develops. Clinical presentation and diagnosis of PML are critical for early intervention. Symptoms may include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking or memory, confusion, and personality changes. Diagnosis is confirmed through brain magnetic resonance imaging (MRI) showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Because PML can progress rapidly, prompt recognition is essential.

Mechanism of PML Development in Tysabri Patients

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to blood vessel walls, preventing them from crossing the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus. In immunocompromised patients, JC virus can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three established risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The FDA label notes that these factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri.

Clinical Evidence and Risk Context

Clinical trial data provide evidence of PML occurrence. In studies, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML can develop even within the first two years of treatment. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The FDA boxed warning clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability. It also instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that monitoring occurs.

Legal Considerations for Tysabri-Related PML

For patients who have developed PML after Tysabri treatment, legal considerations may include whether the prescribing physician adequately discussed the risks and whether the patient was properly monitored. The timeline between exposure and documented harm is variable. PML can occur after a few doses or after several years of treatment. In clinical trials, one case occurred after eight doses, while others occurred after longer treatment durations. The FDA label emphasizes that longer treatment duration, especially beyond two years, increases risk. Attorney-related considerations for affected patients include the possibility of filing a lawsuit against the manufacturer for failure to warn or for defective design. Eligibility for such lawsuits typically requires that the patient received Tysabri, developed PML, and that the harm was not adequately communicated or preventable. Patients should consult with a qualified attorney who specializes in pharmaceutical litigation to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms and diagnosis of PML?

Symptoms include progressive weakness, clumsiness, visual disturbances, confusion, and personality changes. Diagnosis is confirmed by brain MRI showing white matter lesions and detection of JC virus DNA in cerebrospinal fluid.

What are the risk factors for developing PML while on Tysabri?

Three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML after taking Tysabri?

Eligibility typically requires documented Tysabri exposure, a confirmed PML diagnosis, and evidence that the risks were not adequately communicated or monitored. Consult a pharmaceutical litigation attorney to evaluate your case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.